“3P (Patient-Pulse-Prognosis) in heart failure” survey: focus on heart rate

Česká verzia

Authors: Juraj Dúbrava
Authors place of work: Oddelenie neinvazívnej kardiológie Nemocnice sv. Cyrila a Metoda, UN Bratislava, Slovenská republika
Published in the journal: Vnitř Lék 2016; 62(1): 17-24
Category: Original Contributions

Summary

Background:
The data on heart rate in chronic heart failure in the real-world practice in Slovakia are not sufficiently known. The objective of the “3P (Patient-Pulse-Prognosis) in heart failure” survey was to collect epidemiological data with particular emphasis on heart rate control in sinus rhythm.

Methods:
The survey was performed by 162 cardiologists and internists. Outpatients or clinically stable hospitalized patients diagnosed with chronic heart failure were included in the survey. No exclusion criteria for patients enrollment were used. A total of 4738 patients were prospectively included.

Results:
93.6% of patients with heart failure were taking beta-blockers. At least 50% of the target dose according to ESC had 48.1% of patients receiving beta-blockers. Heart rate ≥ 70 bpm was present in 55.3% of all patients and in 48.1% of patients with sinus rhythm. Out of the total unselected study population we identified 28.0% of patients with symptomatic heart failure (NYHA class II-IV), sinus rhythm, and suboptimal heart rate ≥ 70 bpm. The prevalence of heart rate ≥ 70 bpm was significantly higher in patients with beta-blocker dose < 50% of the target dose according to ESC compared with patients receiving ≥ 50% of the target dose (58.0% vs 52.4%, p < 0.001). Heart rate ≥ 70 bpm was significantly more common in patients with history of hospitalization for heart failure compared with patients who have not been hospitalized (56.8% vs 53.7%, p < 0.05). The physicians planned up-titration of the dose only in 20.2% of patients treated with beta-blockers.

Conclusions:
Despite extensive beta-blockers therapy we found suboptimal heart rate control in chronic heart failure. Patients on lower doses of beta-blockers (< 50 % of the target dose according to ESC) and patients with history of hospitalization for heart failure were noted to be in significantly higher risk of unsatisfactory heart rate. The proportion of patients with intended up-titration of the beta-blocker dose was low. Therefore it is necessary to reduce heart rate by alternative or complementary pharmacotherapy.

Key words:
beta-blockers – heart failure – heart rate – ivabradine

Zdroje

1. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372(9641): 817–821.

2. Castagno D, Skali H, Takeuchi M et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol 2012; 59(20): 1785–1795.

3. Špinar J, Vítovec J, Špinarová L. Farmakoterapie chronického srdečního selhání po prvních 10 letech 21. století. Vnitř Lék 2011; 57(11): 959–965.

4. Böhm M, Perez AC, Jhund PS et al. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). Eur J Heart Fail 2014; 16(7): 778–787.

5. Takada T, Sakata Y, Miyata S et al. Impact of elevated heart rate on clinical outcomes in patients with heart failure with reduced and preserved ejection fraction: a report from the CHART-2 Study. Eur J Heart Fail 2014; 16(3): 309–316.

6. Maeder MT, Kaye DM. Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction. Int J Cardiol 2012; 155(2): 249–256.

7. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787–1847.

8. Fruhwald FM, Ulmer H, Pacher R et al. Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry. Wien Klin Wochenschr 2011; 123(11–12): 378–383.

9. O’Connor CM, Stough WG, Gallup DS et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005; 11(3): 200–205.

10. Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50(8): 768–777.

11. Kociol RD, Peterson ED, Hammill BG et al. National survey of hospital strategies to reduce heart failure readmissions: findings from the Get with the Guidelines-Heart Failure registry. Circ Heart Fail 2012; 5(6): 680–687.

12. von Scheidt W, Zugck C, Pauschinger M et al. Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol 2014; 103(13): 1006–1014.

13. Jonsson A, Edner M, Alehagen U et al. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail 2010; 12(1): 25–31.

14. Grundtvig M, Gullestad L, Hole T et al. Characteristics, implementation of evidence-based management and outcome in patients with chronic heart failure: results from the Norwegian heart failure registry. Eur J Cardiovasc Nurs 2011; 10(1): 44–49.

15. Maggioni AP, Anker SD, Dahlström U et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013; 15(10): 1173–1184.

16. Tebbe U, Tschöpe C, Wirtz JH et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 2014; 103(8): 665–673.

17. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154(2): 260–266.

18. Borer JS, Böhm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J 2012; 33(22): 2813–2820.

19. Kapoor JR, Heidenreich PA. Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail. 2010; 16(10): 806–811.

20. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther 2014; 31(9): 961–974.

21. de Groote P, Isnard R, Assyag P et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007; 9(12): 1205–1211.

22. Jensen J, Hedin L, Widell C et al. Characteristics of heart failure in the elderly-a hospital cohort registry-based study. Int J Cardiol 2008; 125(12): 191–196.

23. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150(11): 784–794.

24. Swedberg K, Komajda M, Böhm M et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59(22): 1938–1945.

25. Špinar J, Špinarová L, Vítovec J et al. Srovnání amerických a evropských (českých) doporučení pro diagnostiku a léčbu chronického srdečního selhání. Vnitř Lék 2014; 60(4): 366–374.

26. Hernandez AF, Hammill BG, O’Connor CM et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53(2): 184–192.

27. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875–885.

28. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102(1): 11–22.

29. Borer JS, Böhm M, Ford I et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014; 113(3): 497–503.

30. Santos M, Leite-Moreira AF. Effect of ivabradine on heart failure with preserved ejection fraction. J Am Coll Cardiol 2014; 63(6): 608–609.

31. Cullington D, Goode KM, Cleland JG et al. Limited role for ivabradine in the treatment of chronic heart failure. Heart 2011; 97(23): 1961–1966.